期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 33, 期 4, 页码 2102-2109出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2021.1919288
关键词
Rituximab; pemphigus; long-term efficacy; long-term safety
类别
Rituximab appears to be effective for treating pemphigus, with 84.9% of patients achieving complete remission in this study. Additional rituximab cycles may help prolong remission in pemphigus patients resistant to conventional therapies. Prospective trials are needed to determine the optimal dosing protocol.
Background Rituximab appears to be effective for treating pemphigus, although there are limited long-term data. Methods This retrospective single-center study evaluated patients with conventional treatment-resistant pemphigus who received rituximab during September 2010-December 2019. The first rituximab cycle was based on the rheumatoid arthritis protocol in all patients except one patient, and additional single doses (500 mg or 1000 mg) were administered after clinical and/or serological relapse. The consensus definitions were used for complete remission off therapy, complete remission on minimal therapy, and clinical relapse. Serological relapse was defined as a progressive >= 2-fold increase in anti-desmoglein titers (vs. previous the measurement). Results The study included 52 patients with pemphigus vulgaris and 1 patient with pemphigus foliaceus. The mean number of infusions was 5 and the average follow-up after the first infusion was 56 months. The average time to clinical and/or serological relapse was 12 months. Complete remission was achieved in 84.9% of patients, including after the first rituximab cycle in 25 patients (47.1%). Two patients died during the follow-up period. Conclusion Additional rituximab cycles may help achieve and prolong remission in patients with moderate-to-severe pemphigus resistant to conventional therapies. However, prospective trials are needed to identify the optimal dosing protocol.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据